Juvenile idiopathic arthritis (JIA) is an umbrella term for arthritis of unknown origin, lasting
for> 6 weeks with onset before 16 years of age. JIA is the most common chronic …

In the past decade, the emergence of machine learning (ML) applications has led to
significant advances towards implementation of personalised medicine approaches for …

Objective To provide updated guidelines for pharmacologic management of juvenile
idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint …

Objective To develop treatment recommendations for children with juvenile idiopathic
arthritis manifesting as non‐systemic polyarthritis, sacroiliitis, or enthesitis. Methods The …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

Background Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody,
is effective in the treatment of juvenile idiopathic arthritis (JIA). We tested the efficacy of …

Juvenile idiopathic arthritis (JIA) is defined by the International League of Associations for
Rheumatology (ILAR) as arthritis of unknown etiology that begins before the sixteenth …

To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert
surveys, logistic regression, and conjoint analysis were used to develop 287 definitions …

Juvenile idiopathic arthritis (JIA), as a chronic condition, is associated with significant
disease-and treatment-related morbidity, thus impacting children's quality of life. In order to …

Objective The present study was undertaken to assess the long‐term course, remission rate,
and disease burden in juvenile idiopathic arthritis (JIA) 18 years after disease onset in a …